All In Biotech

Drug Trial Radar · NCT04326829

QL1604 Monotherapy for dMMR or MSI-H Advanced Solid Tumors

A Single-arm, Multi-center, Phase Ⅱ Clinical Study to Evaluate Efficacy and Safety of QL1604 Monotherapy for the Treatment of Unresectable or Metastatic Mismatch Repair Deficient (dMMR) or Microsatellite Instability-high (MSI-H) Solid Tumors That Failed to Respond to Standard Therapy

Last checked: Nov 19, 2026Latest source record: Dec 7, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

86

Planned (sponsor's estimate)

Start

Jul 8, 2020

Primary completion

Dec 2022

Study completion Jul 2023

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Mar 30, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, patients with previously-treated locally-advanced or metastatic mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal carcinoma (CRC) and other solid tumors will be treated with QL1604 monotherapy.

Conditions

  • Advanced Malignant Tumor

Interventions

  • QL1604Drug

    QL1604, IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORRTime frame: up to 2 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Fudan University Cancer Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.